How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Various sociodemographic factors associate with initial anti-VEGF doses, including race, ethnicity and insurance. Although eyes with frequent initial doses maintained higher VA than those without, they also receive more injections over time. Further research may elucidate the impact of frequent initial doses versus total injection number on DME outcomes.
Authors
- Eunice Kim (ORCID: https://orcid.org/0000-0003-4407-0484)
- Theodore Leng (ORCID: https://orcid.org/0000-0002-8461-3562)
- David Tabano (ORCID: https://orcid.org/0000-0001-7657-0809)
- Vincent Garmo (ORCID: https://orcid.org/0000-0003-3073-0373)
- Andrew LaPrise (ORCID: https://orcid.org/0000-0003-3717-1279)
- Meghan Hatfield
- Rishi P. Singh (ORCID: https://orcid.org/0000-0001-5859-8162)
- Blanche L. Kuo (ORCID: https://orcid.org/0000-0001-9227-9560)
Institutions
- Cleveland Clinic (US)
- University School (US)
- Cleveland Eye Clinic (US)
- Case Western Reserve University (US)
- Stanford University (US)
Publication Details
- Journal
- BMC Ophthalmology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1186/s12886-024-03797-9
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08
Funders
- Research to Prevent Blindness
- F. Hoffmann-La Roche
- National Institutes of Health
- Genentech